These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 20220270

  • 1. Successful transfer from insulin to oral sulfonylurea in a 3-year-old girl with a mutation in the KCNJ11 gene.
    Al-Mahdi M, Al Mutair A, Al Balwi M, Hussain K.
    Ann Saudi Med; 2010; 30(2):162-4. PubMed ID: 20220270
    [Abstract] [Full Text] [Related]

  • 2. Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide.
    Bremer AA, Ranadive S, Lustig RH.
    Pediatr Diabetes; 2008 Jun; 9(3 Pt 1):236-9. PubMed ID: 18221420
    [Abstract] [Full Text] [Related]

  • 3. Transition from insulin to glyburide in a 4-month-old girl with neonatal diabetes mellitus caused by a mutation in KCNJ11.
    Chan YM, Laffel LM.
    Pediatr Diabetes; 2007 Aug; 8(4):235-8. PubMed ID: 17659066
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM.
    Mohamadi A, Clark LM, Lipkin PH, Mahone EM, Wodka EL, Plotnick LP.
    Pediatr Diabetes; 2010 May; 11(3):203-7. PubMed ID: 19686306
    [Abstract] [Full Text] [Related]

  • 8. [Low doses of sulphonyluria as a successful replacement for insulin therapy in a patient with neonatal diabetes due to a mutation of KCNJ11 gene encoding Kir6.2].
    Ille J, Putarek NR, Radica A, Hattersley A, Ellard S, Dumić M.
    Lijec Vjesn; 2010 May; 132(3-4):90-3. PubMed ID: 20540435
    [Abstract] [Full Text] [Related]

  • 9. Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.
    Lau E, Correia C, Freitas P, Nogueira C, Costa M, Saavedra A, Costa C, Carvalho D, Fontoura M.
    Arch Endocrinol Metab; 2015 Dec; 59(6):559-61. PubMed ID: 26331221
    [Abstract] [Full Text] [Related]

  • 10. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11.
    Mlynarski W, Tarasov AI, Gach A, Girard CA, Pietrzak I, Zubcevic L, Kusmierek J, Klupa T, Malecki MT, Ashcroft FM.
    Nat Clin Pract Neurol; 2007 Nov; 3(11):640-5. PubMed ID: 17982434
    [Abstract] [Full Text] [Related]

  • 11. Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences.
    Flechtner I, de Lonlay P, Polak M.
    Diabetes Metab; 2006 Dec; 32(6):569-80. PubMed ID: 17296510
    [Abstract] [Full Text] [Related]

  • 12. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2.
    Zung A, Glaser B, Nimri R, Zadik Z.
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5504-7. PubMed ID: 15531505
    [Abstract] [Full Text] [Related]

  • 13. Functional effects of mutations at F35 in the NH2-terminus of Kir6.2 (KCNJ11), causing neonatal diabetes, and response to sulfonylurea therapy.
    Proks P, Girard C, Baevre H, Njølstad PR, Ashcroft FM.
    Diabetes; 2006 Jun; 55(6):1731-7. PubMed ID: 16731836
    [Abstract] [Full Text] [Related]

  • 14. Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes.
    Babiker T, Vedovato N, Patel K, Thomas N, Finn R, Männikkö R, Chakera AJ, Flanagan SE, Shepherd MH, Ellard S, Ashcroft FM, Hattersley AT.
    Diabetologia; 2016 Jun; 59(6):1162-6. PubMed ID: 27033559
    [Abstract] [Full Text] [Related]

  • 15. Sulfonylurea-responsive diabetes in childhood.
    Landau Z, Wainstein J, Hanukoglu A, Tuval M, Lavie J, Glaser B.
    J Pediatr; 2007 May; 150(5):553-5. PubMed ID: 17452235
    [Abstract] [Full Text] [Related]

  • 16. KCNJ11 in-frame 15-bp deletion leading to glibenclamide-responsive neonatal diabetes mellitus in a Chinese child.
    Yang W, Wei H, Sang Y.
    J Pediatr Endocrinol Metab; 2013 May; 26(7-8):743-6. PubMed ID: 24266052
    [Abstract] [Full Text] [Related]

  • 17. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.
    Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, Howard N, Srinivasan S, Silva JM, Molnes J, Edghill EL, Frayling TM, Temple IK, Mackay D, Shield JP, Sumnik Z, van Rhijn A, Wales JK, Clark P, Gorman S, Aisenberg J, Ellard S, Njølstad PR, Ashcroft FM, Hattersley AT.
    N Engl J Med; 2004 Apr 29; 350(18):1838-49. PubMed ID: 15115830
    [Abstract] [Full Text] [Related]

  • 18. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene.
    Slingerland AS, Nuboer R, Hadders-Algra M, Hattersley AT, Bruining GJ.
    Diabetologia; 2006 Nov 29; 49(11):2559-63. PubMed ID: 17047922
    [Abstract] [Full Text] [Related]

  • 19. A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain.
    Shimomura K, Hörster F, de Wet H, Flanagan SE, Ellard S, Hattersley AT, Wolf NI, Ashcroft F, Ebinger F.
    Neurology; 2007 Sep 25; 69(13):1342-9. PubMed ID: 17652641
    [Abstract] [Full Text] [Related]

  • 20. DEND syndrome due to V59A mutation in KCNJ11 gene: unresponsive to sulfonylureas.
    Itoh S, Matsuoka H, Yasuda Y, Miyake N, Suzuki K, Yorifuji T, Sugihara S.
    J Pediatr Endocrinol Metab; 2013 Sep 25; 26(1-2):143-6. PubMed ID: 23382304
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.